An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter

被引:306
|
作者
Cleutjens, KBJM
vanderKorput, HAGM
vanEekelen, CCEM
vanRooij, HCJ
Faber, PW
Trapman, J
机构
关键词
D O I
10.1210/me.11.2.148
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Prostate-specific antigen (PSA) is expressed at a high level in the luminal epithelial cells of the prostate and is absent or expressed at very low levels in other tissues. PSA expression can be regulated by androgens. Previously, two functional androgen-response elements were identified in the proximal promoter of the PsA gene. To detect additional, more distal control elements, DNaseI-hypersensitive sites (DHSs) upstream of the PSA gene were mapped in chromatin from the prostate-derived cell line LNCaP grown in the presence and absence of the synthetic androgen R1881. In a region 4.8 to 3.8 kb upstream of the transcription start site of the PSA gene, a cluster of three DHSs was detected. The middle DNAseI-hypersensitive site (DHSII, at similar to-4.2 kb) showed strong androgen responsiveness in LNCaP cells and was absent in chromatin from HeLa cells. Further analysis of the region encompassing DHSII provided evidence for the presence of a complex, androgen-responsive and cell-specific enhancer. In transient transfected LNCaP cells, PSA promoter constructs containing this upstream enhancer region showed approximately 3000-fold higher activity in the presence than in the absence of R1881. The core region of the enhancer could be mapped within a 440-bp fragment. The enhancer showed synergistic cooperation with the proximal PsA promoter and was found to be composed of at least three separate regulatory regions. In the center, a functionally active, high-affinity androgen receptor binding site (GGAACATATTGTATC) could be identified. Mutation of this element almost completely abolished PSA promoter activity. Transfection experiments in prostate and nonprostate cell lines showed largely LNCaP cell specificity of the upstream enhancer region, although some activity was found in the T47D mammary tumor cell line.
引用
收藏
页码:148 / 161
页数:14
相关论文
共 50 条
  • [41] Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials
    Nikitas, John
    Ong, Wee Loon
    Carrier, Nathalie
    Romero, Tahmineh
    Millar, Jeremy
    Steinberg, Michael L.
    Rettig, Matthew B.
    Boutros, Paul C.
    Reiter, Robert
    Nickols, Nicholas G.
    Valle, Luca
    Mcguire, Sean E.
    Spratt, Daniel E.
    Souhami, Luis
    Roy, Soumyajit
    Martin, Jarad M.
    Joseph, David
    Nabid, Abdenour
    Kishan, Amar U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 119 (03): : 826 - 831
  • [42] Tissue Prostate-Specific Antigen Facilitates Refractory Prostate Tumor Progression via Enhancing ARA70-Regulated Androgen Receptor Transactivation Editorial Comment
    Atala, Anthony
    JOURNAL OF UROLOGY, 2009, 181 (04): : 1956 - 1957
  • [43] Identification of two novel cis-elements in the promoter of the prostate-specific antigen gene that are required to enhance androgen receptor-mediated transactivation
    Zhang, JY
    Zhang, SB
    Murtha, PE
    Zhu, W
    Hou, SSM
    Young, CYF
    NUCLEIC ACIDS RESEARCH, 1997, 25 (15) : 3143 - 3150
  • [44] Prostate-specific membrane antigen (PSMA), androgen modulation, folic acid, and high-grade prostate cancer: An intriguing nexus needing attention
    Goldstein, Mark R.
    Mascitelli, Luca
    MEDICAL HYPOTHESES, 2023, 174
  • [45] Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group
    Bubley, GJ
    Carducci, M
    Dahut, W
    Dawson, N
    Daliani, D
    Eisenberger, M
    Figg, WD
    Freidlin, B
    Halabi, S
    Hudes, G
    Hussain, M
    Kaplan, R
    Myers, C
    Oh, W
    Petrylak, DP
    Reed, E
    Roth, B
    Sartor, O
    Scher, H
    Simons, J
    Sinibaldi, V
    Small, EJ
    Smith, MR
    Trump, DL
    Vollmer, R
    Wilding, G
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3461 - 3467
  • [46] Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations
    Suzuki, S
    Tadakuma, T
    Asano, T
    Hayakawa, M
    CANCER RESEARCH, 2001, 61 (04) : 1276 - 1279
  • [47] The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus
    Kim, J
    Jia, L
    Stallcup, MR
    Coetzee, GA
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2005, 34 (01) : 107 - 118
  • [48] Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy
    Kurita, Y
    Masuda, H
    Suzuki, K
    Fujita, K
    Kawabe, K
    BRITISH JOURNAL OF UROLOGY, 1997, 80 (01): : 78 - 83
  • [49] Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN
    Saad, Fred
    Small, Eric J.
    Feng, Felix Y.
    Graff, Julie N.
    Olmos, David
    Hadaschik, Boris A.
    Oudard, Stephane
    Londhe, Anil
    Bhaumik, Amitabha
    Lopez-Gitlitz, Angela
    Thomas, Shibu
    Mundle, Suneel D.
    Chowdhury, Simon
    Smith, Matthew R.
    EUROPEAN UROLOGY, 2022, 81 (02) : 184 - 192
  • [50] Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaive patients with metastatic castration-resistant prostate cancer
    Lee, Chung-Lin
    Chang, Ying-Hsu
    Liu, Chung-Yi
    Hsieh, Ming-Li
    Huang, Liang-Kang
    Chu, Yuan-Cheng
    Kan, Hung-Cheng
    Lin, Po-Hung
    Yu, Kai-Jie
    Chuang, Cheng-Keng
    Wu, Chun-Te
    Pang, See-Tong
    Shao, I-Hung
    INVESTIGATIVE AND CLINICAL UROLOGY, 2022, 63 (05) : 546 - 553